Jazz Pharmaceuticals

At a glance

Jazz Pharmaceuticals reported 2025 revenue of $4.27B, up 4.9% from $4.07B in 2024. Over 4 years since 2021 ($3.09B), that is growth of about 8.4% a year. Operating margin was -10.1%, down from 5.5% in 2021. 2025 was the highest revenue year in this period. The company posted a loss in 2022 and 2025.

In the last 12 months 11 insiders reported 0 open-market purchases and 31 sales ($69.8M). 16 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $19.2M by EVP, Global Head of R&D & CMO Robert Iannone on Aug 31, 2026.

Jazz Pharmaceuticals filed 16 current reports (Form 8-K) in the last 12 months, most often for results of operations (6), material agreement (3), officer or director change (2) and new financial obligation (2). The latest officer or director change was reported on Oct 9, 2026. It reported a material agreement or a completed acquisition or disposal 3 times.

1 of the 20 investors tracked here held Jazz Pharmaceuticals at the last quarter end, worth $135.4M combined. It is the largest weight for Renaissance Technologies (0.2% of its portfolio). Reduced: Renaissance Technologies.

Annual results

Fiscal year ends Dec 31 · incorporated in L2

Tracked investors holding (13F)

Weight is the share of each investor's portfolio, as of the quarter end.